GENECAST is a genetic testing start-up with liquid biopsy, specialized in monitoring cancer with original Allele-Discriminating Priming System(ADPS) which boasts an unprecedented sensitivity, 0.0001%. GENECAST’s mission is to make cancer a commonly curable disease by straightly face cancer through the highest detection sensitivity. ADPS™ EGFR mutation test kit is in the process of approving FDA PMA Class3 and aims to get approval by 2020.
Besides ctDNA diagnostic technology, researchers are developing new diagnostic technologies.